What Is Your DSO Roll-Up Actually Worth?
Buying practices at a single-location multiple and building a platform that trades at a materially higher one is the whole roll-up thesis. Model your own numbers below and see exactly where the value comes from — multiple arbitrage, operating synergies, or both.
Two numbers decide what a roll-up is worth: the multiple, and the adjusted EBITDA it's multiplied against.
A DSO synergy and roll-up calculator estimates what a group of acquired practices is worth once combined into a single platform, by separating two distinct value drivers: multiple arbitrage (buying at a lower single-practice multiple and consolidating into a platform that trades higher) and synergy value (the extra adjusted EBITDA created by shared back-office, purchasing, and scheduling). That combined, adjusted EBITDA figure isn't just an academic number — it's usually the exact figure an earn-out calculator uses to determine payout. Most dental earn-outs pay out against post-close adjusted EBITDA performance, not gross revenue, so understanding how much of that number comes from real operating improvement versus multiple re-rating changes what a seller should expect, and what a buyer should be willing to guarantee, in the earn-out terms.
Five practices, worked start to finish.
Here's the exact math behind the calculator's default inputs — five practices at $500,000 average EBITDA each, bought at 6x, inside a platform trading at 11x, with 12% synergy captured.
| Metric | Value | How It's Calculated |
|---|---|---|
| Combined (Adjusted) EBITDA | $2,500,000 | 5 practices × $500,000 |
| Acquisition Cost | $15,000,000 | $2,500,000 × 6x |
| Multiple Arbitrage Value | $12,500,000 | $2,500,000 × (11x − 6x) |
| Synergy Value | $3,300,000 | $2,500,000 × 12% × 11x |
| Platform Value | $30,800,000 | Acquisition Cost + Arbitrage + Synergy |
Of the $15.8 million in value created above cost, $12.5 million — nearly 80% — comes from the multiple re-rate alone, not from operating improvement. That's the number sellers should scrutinize hardest in earn-out negotiations: if a buyer's earn-out structure ties payout to hitting adjusted EBITDA targets that assume synergy capture, but the deal's real value is coming from the multiple, a seller can end up bearing integration risk for value they've already effectively sold at close.
Solo sale vs. platform roll-up, same $500,000 EBITDA practice.
The identical practice is worth a very different amount depending on whether it sells alone or as part of a platform — and how much of that difference is arbitrage versus synergy.
| Scenario | Multiple Applied | Per-Practice Value |
|---|---|---|
| Solo sale, single practice | 6x adjusted EBITDA | $3,000,000 |
| Same practice, inside a 5-location platform (arbitrage only) | 11x, no synergy | $5,500,000 |
| Same practice, platform with 12% synergy captured | 11x + synergy | $6,160,000 |
Per-practice value in rows 2 and 3 is the platform's total value divided evenly across five practices — actual deal allocation varies by structure. Figures are illustrative, not a valuation or investment recommendation.
Two separate value drivers. Most operators only see one.
Every roll-up story blends two very different sources of value: paying a lower multiple for practices than the platform itself will trade for (multiple arbitrage), and making the combined business genuinely more profitable through shared overhead, group purchasing, and centralized scheduling (synergy value). This tool separates the two so you can see which one is actually doing the work in your model.
Multiple Arbitrage, Quantified
See the dollar value created purely from buying at single-practice multiples and consolidating into a platform that trades at a higher multiple — before a single dollar of synergy is realized.
Synergy Value, Isolated
Model the incremental EBITDA from shared back-office, group purchasing, and scheduling separately from the multiple re-rate, so you know which lever is doing the heavier lifting.
Total Platform Value
See your projected platform value against your total acquisition cost — the number that tells you whether the roll-up math actually works at your assumptions.
Across recent dental M&A activity, the spread between single-location multiples (roughly 4–8x EBITDA) and platform-tier multiples (roughly 9–15x EBITDA for scaled, well-run groups) is consistently the largest single driver of DSO roll-up economics — often larger than the operating synergies themselves. That doesn't make synergies unimportant; it makes them the second lever, not the first.
Five inputs. A clear breakdown.
Enter your roll-up assumptions below. Defaults are pre-filled with reasonable illustrative figures — replace them with your own.
Roll-Up Size
Number of practices and average annual EBITDA per practice.
Acquisition Multiple
What you're actually paying per practice, in EBITDA multiples.
Platform Multiple
What a platform of this scale typically trades for.
See the Breakdown
Arbitrage value and synergy value, shown separately and combined.
DSO Synergy & Roll-Up Value Calculator
No email required — your numbers stay in your browser and are never collected or stored.
Building or evaluating a dental roll-up?
DSI covers the full playbook — capital planning, equipment standardization, and the operating discipline that separates platforms built to last from the ones under pressure the moment growth slows.
Questions operators ask about roll-up value
It's the value created by acquiring practices at a lower, single-location EBITDA multiple and combining them into a platform that trades at a materially higher, platform-tier multiple — without changing the underlying operations at all.
No. Multiple arbitrage and operating synergies are both real value drivers, and this tool intentionally separates them so you can see which one your specific deal actually depends on.
They reflect commonly cited ranges in recent dental M&A activity — roughly 4–8x EBITDA for single-location and add-on deals, and roughly 9–15x for scaled, platform-tier groups. Your actual terms will depend on specialty mix, growth rate, geography, and buyer.
Most operators model 10–20% of combined EBITDA from shared back-office functions, group purchasing, and centralized scheduling. Assumptions above that range should be backed by a specific, itemized integration plan, not a general expectation.
Generally yes, up to a point — but the multiple re-rate reflects buyer perception of scale, systems, and de-risked cash flow, not size alone. A large but poorly integrated platform can trade at a discount to a smaller, cleaner one.
No. This is an educational, illustrative model built on your own inputs and general market ranges. It does not constitute a valuation, appraisal, or investment recommendation. Work with an M&A advisor, accountant, and attorney before acting on any roll-up decision.
Adjusted EBITDA takes a practice's EBITDA and normalizes it for one-time or owner-specific items — above-market owner compensation, one-time equipment purchases, non-recurring legal fees — so the number reflects ongoing earning power a buyer can rely on. It's the figure both the acquisition multiple and the platform multiple in this tool are applied against, and it's almost always the figure an earn-out is measured against post-close.
An earn-out calculator determines what a seller gets paid based on the practice hitting agreed post-close adjusted EBITDA targets. This tool shows where that adjusted EBITDA number can come from — multiple arbitrage locked in at close, versus synergy value that depends on integration actually happening. A seller negotiating an earn-out should know which piece their payout is really riding on.
